Skip to content
19 November · 06:30 UTCFollow AstraZeneca by emailFollow

AZN · Pharma and healthcare · one day

AstraZeneca (AZN): news on Thursday 19 November 2026

News from the 24 hours to Thursday morning, 19 November 2026.

Tone of the day

+5.5positive
Relevant headlines23of 26 read
Stories8grouped by event

What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

Why it scored this way

Coverage was mainly about the extended Tempus AI data agreement, US approval of a new Imfinzi bladder cancer regimen and a letter of intent between its Indian arm and Strand Life Sciences. A supportive broker view and a rebound after results add to the positive lean, though one report noted share price weakness.

What drove it

  • Imfinzi bladder approval
  • Tempus AI deal extension
  • India partnership

Around this day

DayToneHeadlines
Fri 13 Nov+5.38
Sat 14 Nov+5.539
Sun 15 Nov+7.59
Mon 16 Nov+4.56
Tue 17 Nov+9.745
Wed 18 Nov+7.029
Thu 19 Nov+5.523

8 stories · 23 headlines · strongest first

Pharma and healthcare on 19 NovemberFTSE 100 that day
ToneWhat the article reported, and why it scored that waySource
AstraZeneca pledges $200m to Tempus AI as their agreement is extended +4.510 headlines today · Outlets report a five-year extension through 2031.
+5.0Services contract prolonged for several years.MarketScreener (opens the article) ↗
+5.0Oncology agreement extended, showing continued investment.TradingView (opens the article) ↗
+5.0Sizeable multi-year data commitment supports oncology pipeline work.MLQ.ai (opens the article) ↗
+5.0Data partnership with AI firm continues, supporting oncology research.MarketScreener (opens the article) ↗
+5.0Oncology data deal renewed with large commitment.tokenpost.com (opens the article) ↗
+4.7Partnership prolonged with five-year funding commitment.TradingView (opens the article) ↗
+4.2Amended deal includes new multi-year spending commitment.Investing.com UK (opens the article) ↗
+4.2Services agreement extended.TipRanks (opens the article) ↗
+3.3Formal amendment to existing services contract.TradingView (opens the article) ↗
+3.3Contract amendment continues existing relationship.Moomoo (opens the article) ↗
Strand Life Sciences and AstraZeneca Pharma India sign letter of intent +3.75 headlines today · 15 in all, since 18 November · Outlets report an LoI to explore healthcare collaboration.
+6.7Shares gained after the Indian tie-up news.Inshorts (opens the article) ↗
+3.3Indian arm signs preliminary agreement to explore healthcare collaboration; small positive.BioSpectrum India (opens the article) ↗
+3.3Indian arm signs letter of intent for healthcare partnership.Voice of Healthcare (opens the article) ↗
+3.3Indian unit and Strand to explore collaboration.Digital Health News (opens the article) ↗
+3.3Indian unit explores healthcare tie-up via non-binding letter.Medical Dialogues (opens the article) ↗
FDA approves Imfinzi regimen for bladder cancer +10.02 headlines today · 17 in all, since 14 November · Reports say the FDA cleared the Imfinzi bladder regimen.
+8.3Regulatory clearance for new use of key cancer drug.AD HOC NEWS (opens the article) ↗
+8.3Approval of new bladder cancer treatment regimen.AD HOC NEWS (opens the article) ↗
AstraZeneca share price moves +1.32 headlines today · Pieces cover a rebound this week and selling pressure near support.
+7.5Shares recovering following better-than-expected results.Kalkine Media (opens the article) ↗
−5.0Share price weakness under selling pressure.Traders Union (opens the article) ↗
Jefferies raises AstraZeneca target, keeps Buy +9.21 headline today · 2 in all, since 18 November · Jefferies believes AstraZeneca can achieve its $80bn sales goal.
+9.2Broker supportive and sees long-term revenue ambition as achievable.Proactive financial news (opens the article) ↗
Rhythm Pharma bidding war speculation +2.51 headline today · Seeking Alpha discusses a possible AstraZeneca/Lilly bid.
+2.5Speculation about possible bid interest in a biotech; uncertain, mildly positive.Seeking Alpha (opens the article) ↗
Summit starts sixth Phase III ivonescimab trial against Imfinzi −2.51 headline today · Summit Therapeutics has begun a trial of ivonescimab compared with Imfinzi in lung cancer at stage III.
−2.5Rival trial targets head-to-head comparison with its lung cancer drug.MLQ.ai (opens the article) ↗
AstraZeneca signs cloud ERP deal with SAP +2.71 headline today · 7 in all, since 15 November · Coverage notes deeper SAP cloud ties.
+1.7Deepening cloud software relationship; minor operational story.AD HOC NEWS (opens the article) ↗

Each article has its own score. The lines are our own summary; follow the source link to read the article itself.

Follow by email

A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

How it works. Every morning an AI model reads the UK business news about each FTSE 100 company and scores how good or bad it is for the company, from −10 to +10. Pages update by about 07:45 UK time.

Not investment advice. MarketFrame rates the tone of news coverage. It is general information, not a recommendation to buy or sell anything. The scores are not share-price data or forecasts: a good score doesn't mean a share will rise, and a bad one doesn't mean it will fall.

Data to 06:30 UTC, 19 November · 909 headlines · 82 companiesMade by Adapt Progress Evolve Limited, a UK company · Privacy · Terms · Who we are · RSS · API · llms.txt